OpenLegislation

Article 2 F1

United Kingdom

Original text. Later amendments are not shown.

For the purposes of this Regulation the following definitions shall apply:

  1. (a)

    ‘F2scheduled substance’ means any substance listed in the Annex that can be used for the illicit manufacture of narcotic drugs or psychotropic substances, including mixtures and natural products containing such substances, but excluding mixtures and natural products which contain scheduled substances and which are compounded in such a way that the scheduled substances cannot be easily used or extracted by readily applicable or economically viable means, F3medicinal products as defined in regulation 2 (medicinal products) of the Human Medicines Regulations and veterinary medicinal products as defined in regulation 2 of the Veterinary Medicines Regulations 2013;

  2. (b)

    ‘non-scheduled substance’ means any substance which, although not listed in the Annex, is identified as having been used for the illicit manufacture of narcotic drugs or psychotropic substances;

  3. (c)

    F4‘import’ means any entry of scheduled substances having the status of non-domestic goods into F5Great Britain;

  4. (d)

    F6‘export’ means any departure of scheduled substances from F7Great Britain;

  5. (e)

    ‘intermediary activities’ means any activity to arrange purchase and sale or supply of scheduled substances carried out by any natural or legal person who aims to obtain agreement between two parties or to do so through acting on behalf of at least one of these parties without taking these substances into its possession or taking control of the carrying out of such transaction; this definition shall also include any activity carried out by any natural or legal person established in F8Great Britain involving purchase and sale or supply of scheduled substances without these substances being introduced into Great Britain;

  6. (f)

    ‘operator’ means any natural or legal person engaged in import, export of scheduled substances or intermediary activities relating thereto, including persons pursuing the activity of making customs declarations for clients on a self-employed basis, either as their principal occupation or as a secondary activity related to another occupation;

  7. (g)

    ‘exporter’ means the natural or legal person chiefly responsible for export activities by virtue of the economic and legal relationship to the scheduled substances and to the consignee and, where appropriate, who lodges the customs declaration or on whose behalf the customs declaration is lodged;

  8. (h)

    ‘importer’ means the natural or legal person chiefly responsible for the import activities by virtue of the economic and legal relationship to the scheduled substances and to the consignor and who lodges the customs declaration or on whose behalf the customs declaration is lodged;

  9. (i)

    ‘ultimate consignee’ means any natural or legal person to which the scheduled substances are delivered; this person may be different from the end-user;

  10. (j)

    F9‘natural product’ means—

    1. (i)

      an organism or a part thereof, in any form; or

    2. (ii)

      a naturally occurring substance which is unprocessed or processed only by manual, mechanical or gravitational means, by dissolution in water, by flotation, by extraction with water, by steam distillation or by heating solely to remove water, or which is extracted from air by any means.

  11. (k)

    ‘International Narcotics Control Board’ means the Board established by the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol;

  12. (l)

    F10“special Customs procedures” means special Customs procedures within the meaning of section 3 of, and Schedule 2 to, the Taxation (Cross-border Trade) Act 2018 and “a special Customs procedure” is to be construed accordingly.

Annotations

Textual amendments

F1

Regulation revoked (N.I.) (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), reg. 1(1), Sch.

F2

Substituted by Regulation (EU) No 1259/2013 of the European Parliament and of the Council of 20 November 2013 amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors.

F3

Words in Art. 2(a) substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 14(3)(a); 2020 c. 1, Sch. 5 para. 1(1)

F4

Art. 2(c) substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 14(3)(b); 2020 c. 1, Sch. 5 para. 1(1)

F5

Words in Art. 2(c) substituted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(3)(a)

F6

Art. 2(d) substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 14(3)(c); 2020 c. 1, Sch. 5 para. 1(1)

F7

Words in Art. 2(d) substituted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(3)(a)

F8

Words in Art. 2(e) substituted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(3)(a)

F9

Art. 2(j) substituted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(3)(b)

F10

Art. 2(l) inserted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 14(3)(e); 2020 c. 1, Sch. 5 para. 1(1)